Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
publishing date : 2021 - 09 - 13 tags : Cancer save search
Global Breast Cancer Diagnostics Markets, 2015-2020, 2020-2025F, 2030F: Focus on Imaging, Biopsy, Genomic Tests, & Blood Tests
Published: 2021-09-13 (Crawled : 20:00) - prnewswire.com
DGX | News | $137.55 0.62% 0.0% 1.6M
|
Health Services
|
| O: 0.6%
H: 0.68%
C: -0.01%
PHG | News | $20.97 -0.19% 0.0% 650K
|
Health Technology
|
| O: 0.73%
H: 0.13%
C: -0.4%
ABT | News | $106.89 -0.65% -0.22% 5.1M
|
Health Technology
|
| O: 0.58%
H: 0.5%
C: -0.24%
EXAS | $63.24 -0.46% -0.46% 1.2M
|
Health Technology
|
| O: 0.57%
H: 0.22%
C: -3.18%
AZN | News | $71.175 0.46% 0.46% 6.1M
|
Health Technology
|
| O: 0.67%
H: 0.25%
C: -0.67%
blood test genomic cancer breast cancer diagnostics imaging diagnostic
Adicet Bio Collaborates with Twist Bioscience to Accelerate Discovery of Gamma Delta T Cell Cancer Therapeutics
Published: 2021-09-13 (Crawled : 18:00) - biospace.com/
TWST | $30.81 -2.19% -2.24% 1.4M
|
Health Technology
|
| O: -0.03%
H: 0.51%
C: -4.49%
ACET | News | $1.87 -10.95% -12.3% 1.4M
|
Health Technology
|
| O: 1.18%
H: 1.6%
C: -2.73%
cancer collaboration t-cell bioscience
According to New Multinational Survey, Healthcare Providers Believe Immunotherapy Has Potential to Positively Impact Earlier-Stage Cancer Treatment Landscape Across Tumor Types
Published: 2021-09-13 (Crawled : 14:00) - biospace.com/
BMY | $48.86 -0.27% -0.02% 16M
|
Health Technology
|
| O: 0.54%
H: 0.06%
C: -0.99%
treatment immunotherapy potential positive therapy cancer
IceCure Medical Announces First Peer Reviewed Publication for the 3-Year Interim Analysis of the ICE3 Trial on Cryoablation of Low-Risk, Early-Stage Breast Cancer
Published: 2021-09-13 (Crawled : 14:00) - biospace.com/
ICCM | $1.22 0.82% 94K
|
Manufacturing
|
| O: 0.97%
H: 0.0%
C: -8.96%
cryo risk cancer breast cancer trial
ImmunityBio Announces Positive Durable Responses in BCG Unresponsive Bladder Cancer Patients with a Complete Response Rate of 72%, Median Duration of Complete Response of 19.9 Months, and 85% Remaining Cystectomy-free in Phase 2/3 Trial
Published: 2021-09-13 (Crawled : 13:00) - nantkwest.com
IBRX | $4.815 -12.3% -14.02% 7.9M
|
Manufacturing
|
| O: 0.81%
H: 3.11%
C: -2.01%
media phase 2 phase 2/3 positive cancer trial response bladder
Twist Bioscience Collaborates with Adicet Bio to Accelerate Discovery of Gamma Delta T Cell Cancer Therapeutics
Published: 2021-09-13 (Crawled : 13:00) - biospace.com/
TWST | $30.81 -2.19% -2.24% 1.4M
|
Health Technology
|
| O: -0.03%
H: 0.51%
C: -4.49%
ACET | News | $1.87 -10.95% -12.3% 1.4M
|
Health Technology
|
| O: 1.18%
H: 1.6%
C: -2.73%
cancer collaboration t-cell bioscience
PolyPid Announces Positive Preclinical Data of its Intra-tumoral OncoPLEX in Brain Cancer
Published: 2021-09-13 (Crawled : 12:00) - globenewswire.com
PYPD | $4.4845 4.44% 890
|
Health Technology
|
| O: 0.0%
H: 0.0%
C: -7.81%
positive cancer brain cancer preclinical pre-clinical train
Lantheus and RefleXion Announce Development and Commercialization Collaboration with the Potential to Improve Future Prostate Cancer Treatment
Published: 2021-09-13 (Crawled : 12:00) - globenewswire.com
LNTH | $65.19 1.21% 1.2% 580K
|
Health Technology
|
| O: 1.04%
H: 0.0%
C: -4.42%
treatment commercialization prostate cancer potential collaboration cancer
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.